智通财经APP讯，和铂医药-B(02142)发布公告，于2025年11月4日斥资258.49万港元回购20万股。 ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) ...

Core Insights - The traditional pharmaceutical industry faces significant challenges with lengthy R&D processes and high costs, while AI is emerging as a transformative force to enhance efficiency and capabilities [1][5] - Hu-mAtrIx™ AI platform by Heptares Therapeutics has been launched, marking a significant advancement in AI-driven drug development [1] - The establishment of the AI + Biopharmaceutical Ecosystem Alliance aims to foster collaboration across the industry, enhancing data sharing and innovation [1][5] AI's Impact on Drug Development - AI is revolutionizing drug development by optimizing antibody affinity, specificity, and stability, leading to improved efficacy and reduced side effects [1] - AI applications span from target discovery to clinical trials, significantly reducing costs and time in the drug development process [2] - AI can design complex proteins that traditional methods struggle to create, showcasing its potential to unlock new therapeutic avenues [2] Clinical Trial Enhancements - AI has achieved over 80% accuracy in patient profiling and clinical protocol matching, approaching human expert levels [3] - The integration of AI in clinical trial recruitment can save approximately 40% of the time required for patient enrollment [3] Collaborative Efforts and Industry Transformation - Heptares Therapeutics has initiated partnerships with various companies to enhance AI applications in drug discovery, emphasizing the need for a holistic approach rather than isolated advancements [4] - The AI alliance aims to address the critical challenge of translational prediction in drug development, which has historically been a major risk factor [4][5] - The alliance's focus on data interoperability among pharmaceutical companies, hospitals, and research institutions is crucial for maximizing AI's potential in drug development [5]

Core Insights - A total of 30 companies conducted share buybacks on October 30, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent [1][2] - The total buyback amount for China Feihe was 50.23 million yuan, with 12 million shares repurchased, representing a significant investment in its own stock [1][2] Summary by Company - **China Feihe (06186)**: Repurchased 12 million shares for 50.23 million yuan; cumulative buybacks for the year reached 30.95 million shares, accounting for 0.341% of total share capital [2] - **China Petroleum & Chemical Corporation (00386)**: Repurchased 4.78 million shares for 19.72 million yuan; cumulative buybacks for the year reached 102 million shares, accounting for 0.080% of total share capital [2] - **Stone Four Pharmaceutical Group (02005)**: Repurchased 5 million shares for 15.41 million yuan; cumulative buybacks for the year reached 44.20 million shares, accounting for 1.498% of total share capital [2] - **Lianlian Digital (02598)**: Repurchased 1.38 million shares for 11.31 million yuan; cumulative buybacks for the year reached 4.45 million shares, accounting for 1.065% of total share capital [2] - **Gushengtang (02273)**: Repurchased 290,100 shares for 8.33 million yuan; cumulative buybacks for the year reached 5.88 million shares, accounting for 2.482% of total share capital [2] - **Lianyi Technology-W (09959)**: Repurchased 2.3 million shares for 7.42 million yuan; cumulative buybacks for the year reached 80.04 million shares, accounting for 3.746% of total share capital [2] - **Mongolian Dairy (02319)**: Repurchased 400,000 shares for 5.70 million yuan; cumulative buybacks for the year reached 22.42 million shares, accounting for 0.573% of total share capital [2] - **Kangchen Pharmaceutical (01681)**: Repurchased 280,000 shares for 4.21 million yuan; cumulative buybacks for the year reached 7.84 million shares, accounting for 9.216% of total share capital [2] - **Other Companies**: Various other companies also participated in buybacks, with amounts ranging from 4.51 million yuan to 6 million yuan, and share counts varying significantly [2]

Core Viewpoint - The company, HAPO Pharmaceutical-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will spend HKD 1.3333 million to repurchase 100,000 shares [1] - The buyback price per share ranges from HKD 13.11 to HKD 13.46 [1]

Core Viewpoint - Heptagon Pharmaceuticals-B (02142.HK) announced a share buyback of 100,000 shares at a cost of HKD 1.33 million on October 30 [1] Group 1 - The company executed a buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 1.33 million, reflecting the company's financial strategy [1] - The number of shares repurchased was 100,000, which may influence the stock's liquidity and market perception [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年10月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | ...

Group 1 - The stock of Heptagon Pharmaceuticals-B (02142.HK) has increased by over 4%, currently up by 3.29%, trading at HKD 13.49 [1] - The trading volume reached HKD 52.54 million [1]

Core Viewpoint - The article highlights the successful launch of the AI-driven HCAb model by Heptares Therapeutics, which is expected to revolutionize the development of next-generation therapeutic antibodies and enhance drug discovery processes [1] Company Developments - Heptares Therapeutics' stock rose over 4%, currently trading at 13.49 HKD with a transaction volume of 52.54 million HKD [1] - The company hosted the "Zhi Yao He Po Hui Chuang Xing Chen" Global R&D Day in Shanghai on October 28, where it unveiled its first fully human AI HCAb model [1] Technology and Innovation - The AI HCAb model is based on Heptares' proprietary Harbour Mice platform data and integrates a fine-tuned large language model (LLM) for sequence generation, along with high-precision AI classification and drugability prediction models [1] - This platform establishes a closed-loop process that combines AI design, intelligent screening, and wet lab validation, differentiating it from traditional screening methods [1] Market Implications - The AI HCAb model is anticipated to accelerate the application of fully human HCAb in next-generation therapeutic areas, including multispecific antibodies, XDC, in vivo CAR-T, and inhaled or oral macromolecular drugs [1] - Heptares aims to reshape the landscape of biopharmaceutical development by leveraging AI capabilities and HCAb technology to address unmet clinical needs through data-driven predictive processes [1]

Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), has launched its first fully human AI HCAb model driven by the Hu-mAtrIx™ AI platform, aiming to revolutionize the development of biopharmaceuticals through advanced AI capabilities [1] Group 1: Company Developments - HAPO Pharmaceuticals experienced a stock increase of over 4%, with a current price of 13.49 HKD and a trading volume of 52.54 million HKD [1] - The company successfully held the "Zhiyao HAPO Huichuang Xingchen" global R&D day event in Shanghai on October 28, where the new AI-driven model was officially announced [1] - The AI HCAb model is based on proprietary Harbour Mice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, along with high-precision AI classification and drugability prediction models [1] Group 2: Industry Implications - The AI HCAb model is expected to accelerate the application of fully human HCAb in next-generation therapeutic areas, including multispecific antibodies, XDC, in vivo CAR-T, and inhaled or oral macromolecular drugs [1] - The platform aims to reshape the landscape of biopharmaceutical development by creating a closed-loop process that combines AI design, intelligent screening, and wet lab validation [1] - HAPO Pharmaceuticals is leveraging AI capabilities and HCAb technology to expedite the implementation of innovative therapies and identify unmet clinical needs through data-driven predictive processes [1]